A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Planned End Date changed from 1 Jul 2015 to 1 Jan 2018.